The tumor-stroma ratio (TSR) was evaluated as a promising parameter for breast cancer prognostication in clinically relevant subgroups of patients. The TSR was assessed on hematoxylin and eosin-stained tissue slides of 1,794 breast cancer patients from the Nottingham City Hospital. An independent second cohort of 737 patients from the Netherlands Cancer Institute to Antoni van Leeuwenhoek was used for evaluation. In the Nottingham Breast Cancer series, the TSR was an independent prognostic parameter for recurrence-free survival (RFS; HR 1.35, 95% CI 1.10-1.66, p = 0.004). The interaction term was statistically significant for grade and triple-negative status. Multivariate Cox regression analysis showed a more pronounced effect of the TSR for RFS in grade III tumors (HR 1.89, 95% CI 1.43-2.51, p < 0.001) and triple-negative tumors (HR 1.86, 95% CI 1.10-3.14, p = 0.020). Comparable hazard ratios and confidence intervals were observed for grade and triple-negative status in the ONCOPOOL study. The prognostic value of TSR was not modified by age, tumor size, histology, estrogen receptor status, progesterone receptor status, human epidermal growth factor receptor 2 status or lymph node status. In conclusion, patients with a stroma-high tumor had a worse prognosis compared to patients with a stroma-low tumor. The prognostic value of the TSR is most discriminative in grade III tumors and triple-negative tumors. The TSR was not modified by other clinically relevant parameters making it a potential factor to be included for improved risk stratification.

中文翻译：

---

III级或三阴性乳腺癌患者的肿瘤间质比的预后价值最高。

肿瘤基质比率（TSR）被评估为临床相关患者亚组中乳腺癌预后的有希望参数。对来自诺丁汉市医院的1,794名乳腺癌患者的苏木精和曙红染色的组织切片进行了TSR评估。使用来自荷兰癌症研究所的安东尼·范·列文虎克的737名患者的第二独立队列进行评估。在诺丁汉乳腺癌系列中，TSR是无复发生存的独立预后参数（RFS； HR 1.35，95％CI 1.10-1.66，p = 0.004）。交互作用项对于年级和三负状态具有统计学意义。多变量Cox回归分析显示，TSR对RFS在III级肿瘤（HR 1.89，95％CI 1.43-2.51，p <0.001）和三阴性肿瘤（HR 1.86，95％CI 1.10-3.14，p = 0.020）。在ONCOPOOL研究中，观察到等级和三阴性状态的可比危险比和置信区间。TSR的预后价值不受年龄，肿瘤大小，组织学，雌激素受体状态，孕激素受体状态，人表皮生长因子受体2状态或淋巴结状态的影响。总之，与间质低肿瘤患者相比，间质高肿瘤患者的预后较差。在III级肿瘤和三阴性肿瘤中，TSR的预后价值最高。未通过其他临床相关参数修改TSR，使其成为改善风险分层的潜在因素。在ONCOPOOL研究中，观察到等级和三阴性状态的可比危险比和置信区间。TSR的预后价值不受年龄，肿瘤大小，组织学，雌激素受体状态，孕激素受体状态，人表皮生长因子受体2状态或淋巴结状态的影响。总之，与间质低肿瘤患者相比，间质高肿瘤患者的预后较差。在III级肿瘤和三阴性肿瘤中，TSR的预后价值最高。未通过其他临床相关参数修改TSR，使其成为改善风险分层的潜在因素。在ONCOPOOL研究中，观察到等级和三阴性状态的可比危险比和置信区间。TSR的预后价值不受年龄，肿瘤大小，组织学，雌激素受体状态，孕激素受体状态，人表皮生长因子受体2状态或淋巴结状态的影响。总之，与间质低肿瘤患者相比，间质高肿瘤患者的预后较差。在III级肿瘤和三阴性肿瘤中，TSR的预后价值最具判别性。未通过其他临床相关参数修改TSR，使其成为改善风险分层的潜在因素。人表皮生长因子受体2状态或淋巴结状态。总之，与间质低肿瘤患者相比，间质高肿瘤患者的预后较差。在III级肿瘤和三阴性肿瘤中，TSR的预后价值最具判别性。未通过其他临床相关参数修改TSR，使其成为改善风险分层的潜在因素。人表皮生长因子受体2状态或淋巴结状态。总之，与间质低肿瘤患者相比，间质高肿瘤患者的预后较差。在III级肿瘤和三阴性肿瘤中，TSR的预后价值最具判别性。未通过其他临床相关参数修改TSR，使其成为改善风险分层的潜在因素。